| Popis: |
Since the first description of regional chemotherapy of the liver, many reports [1–4] have demonstrated more theoretical advantage than clinical benefits. Not toxic but catheter complications seemed to limit the potential of the new method [5]. Totally implantable drug pumps and ports (Infusaid, Shiley Infusaid, Inc., Norword, Mass., USA) in the late reduced the risk of technical problems. Using continuous intraarterial floxuridine (FUDR) with an extraction of more than 90% in the liver [6], response rates of 30%–88% were reported [7, 8]. A methodological standard for the first time allowed reliable clinical studies[9–12]. Local treatment seemed superior to conventional systemic chemotherapy, although prolongation of survival was only demonstrated using historical control groups. Our own investigations in this field have tremendously increased the number of patients undergoing hepatic surgery in our institution. Since 1982 we have treated 516 patients with hepatic only malignancies, of whom 128 have undergone liver resection or transplantation. |
